|Boehringer Ingelheim (Canada) Ltd. receives approval for Metacam® 20* for the alleviation of pain and inflammation in sheepFOR IMMEDIATE RELEASE|
Boehringer Ingelheim (Canada) Ltd. receives approval for Metacam® 20* for the alleviation of pain and inflammation in sheep
Burlington, Ontario (May 2, 2016) – Boehringer Ingelheim’s Metacam® 20 has obtained approval in Canada for use in the alleviation of pain and inflammation in sheep. This is the first approval for Metacam® 20 in sheep worldwide.
The marketing authorization was granted based on Colditz et al. Efficacy of Meloxicam in Sheep: Determining the effective dose of meloxicam in a sterile model of inflammation in sheep (2011, unpublished).
In sheep, Metacam® 20 (meloxicam) is given as a single subcutaneous injection of 1.0mL/20kg bodyweight.
The approval comes following a joint submission from Boehringer Ingelheim in Canada, Australia and New Zealand that saw regulatory agencies from each country participate in a collaborative review process. The regulatory agencies for each country maintained the right to determine whether a product was approved for its own market. The joint submission and simultaneous review mark an important achievement in international regulatory cooperation.
Metacam® is non-steroidal anti-inflammatory drug of the oxicam class. Following the joint submission and review process, it is now licensed for use in sheep in t